SNQ – Symbol of National Quality

SNQ is built on evidence-based standards, setting trusted quality and safety benchmarks for healthcare, biomedical, health, and animal care services and products.

  • 9F, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City, Taiwan
  • +886 2 2655 7888
  • snq@snq.com.tw

About

  • Vision & Mission
  • Review Committee
  • Certification Schedule

Application

  • Medical Service
  • Biomedical Product
  • Health Product
  • Animal Care & Products

SNQ Certified

  • Certified Services & Products
  • Certified Organizations
  • Quality Award Winners

International Certification

  • ICHOM PROMs
  • NSF Certification

Quality Insights

  • Apply for Certification →
Organized by|Research Center for Biotechnology and Medicine PolicyOperated by|Broadway International Standards Co., Ltd.© 2026 Broadway International Standards Co., Ltd. All rights reserved.Privacy Policy
SNQ – Symbol of National Quality
繁中
/
EN

Target Population

Mucopolysaccharidosis patients and families

 


Description

Having listened to the agonizing cries of patients and their families suffering from the rare disease mucopolysaccharidosis (MPS), and truly understanding their needs, the MPS patient care team at Mackay Memorial Hospital has, for nearly 20 years, focused on providing the most practical and enhanced medical care. This has been combined with domestic and international professional research capabilities and resources to address the urgent needs of patients and their families one by one. The team also actively participates in international academic research activities aimed at improving diagnostic and treatment processes and enhancing efficacy. Providing holistic care and support for MPS patients and their families is the team's profession, responsibility, and mission.

 


Key Highlights

  • No.1 in the world:

  • First SCI medical paper in the world: A pilot newborn screening program for Mucopolysaccharidosis Type I in Taiwan: Lin SP, Lin HY, Wang TJ, et al. A Pilot Newborn Screening Program for Mucopolysaccharidosis Type I in Taiwan. Orphanet J Rare Dis. 2013;8:147.

  • First SCI medical paper in the world: A nationwide newborn screening program for Mucopolysaccharidoses Type I and II: Chuang CK, Lin HY, Wang TJ, et al. Status of newborn screening and follow-up investigations for Mucopolysaccharidoses I and II in Taiwan. Orphanet J Rare Dis. 2018;13:84.

  • First SCI medical paper in the world: [Earliest and largest in scale] Nationwide screening for Mucopolysaccharidoses Types I, II, IVA, and VI: Chuang CK, Lee CL, Tu RY, et al. Nationwide Newborn screening program for mucopolysaccharidoses in Taiwan and an update of the “gold standard” criteria required to make a confirmatory diagnosis. Diagnostics (Basel), 11, 1583.

 

Service Data

No.1 in the world:

  • The world's earliest and largest newborn screening test for mucopolysaccharidosis types 1, 2, 6, and 4A (pilot study started in 2008, comprehensive newborn screening started in 2015, and more than 850,000 cases have been screened so far) (European, American and Japanese countries: small-scale newborn screening began in 2018, currently less than 100,000 persons have been screened)

  • The world's largest: Mucopolysaccharidosis newborn screening "gene variation" and "genotype-phenotype correlation" database (Europe, the United States and Japan: None)

 


Featured Outcomes

No.1 in the world:

  • First SCI medical paper in the world: A pilot newborn screening program for Mucopolysaccharidosis Type I in Taiwan: Lin SP, Lin HY, Wang TJ, et al. A Pilot Newborn Screening Program for Mucopolysaccharidosis Type I in Taiwan. Orphanet J Rare Dis. 2013;8:147.

  • First SCI medical paper in the world: A nationwide newborn screening program for Mucopolysaccharidoses Type I and II: Chuang CK, Lin HY, Wang TJ, et al. Status of newborn screening and follow-up investigations for Mucopolysaccharidoses I and II in Taiwan. Orphanet J Rare Dis. 2018;13:84.

  • First SCI medical paper in the world: [Earliest and largest in scale] Nationwide screening for Mucopolysaccharidoses Types I, II, IVA, and VI: Chuang CK, Lee CL, Tu RY, et al. Nationwide Newborn screening program for mucopolysaccharidoses in Taiwan and an update of the “gold standard” criteria required to make a confirmatory diagnosis. Diagnostics (Basel), 11, 1583.

 


Safety Outcomes

The overall satisfaction rate of care services for patients with rare diseases is 96.4% in 2025.

 


Satisfaction

The overall satisfaction rate of care services for patients with rare diseases is 96.4% in 2025.

 


International Achievements

No.1 in the world:

  • First SCI medical paper in the world: A pilot newborn screening program for Mucopolysaccharidosis Type I in Taiwan: Lin SP, Lin HY, Wang TJ, et al. A Pilot Newborn Screening Program for Mucopolysaccharidosis Type I in Taiwan. Orphanet J Rare Dis. 2013;8:147.

  • First SCI medical paper in the world: A nationwide newborn screening program for Mucopolysaccharidoses Type I and II: Chuang CK, Lin HY, Wang TJ, et al. Status of newborn screening and follow-up investigations for Mucopolysaccharidoses I and II in Taiwan. Orphanet J Rare Dis. 2018;13:84.

  • First SCI medical paper in the world: [Earliest and largest in scale] Nationwide screening for Mucopolysaccharidoses Types I, II, IVA, and VI: Chuang CK, Lee CL, Tu RY, et al. Nationwide Newborn screening program for mucopolysaccharidoses in Taiwan and an update of the “gold standard” criteria required to make a confirmatory diagnosis. Diagnostics (Basel), 11, 1583.

 


Benefits and Impacts

No.1 in the world:

  • First SCI medical paper in the world: A pilot newborn screening program for Mucopolysaccharidosis Type I in Taiwan: Lin SP, Lin HY, Wang TJ, et al. A Pilot Newborn Screening Program for Mucopolysaccharidosis Type I in Taiwan. Orphanet J Rare Dis. 2013;8:147.

  • First SCI medical paper in the world: A nationwide newborn screening program for Mucopolysaccharidoses Type I and II: Chuang CK, Lin HY, Wang TJ, et al. Status of newborn screening and follow-up investigations for Mucopolysaccharidoses I and II in Taiwan. Orphanet J Rare Dis. 2018;13:84.

  • First SCI medical paper in the world: [Earliest and largest in scale] Nationwide screening for Mucopolysaccharidoses Types I, II, IVA, and VI: Chuang CK, Lee CL, Tu RY, et al. Nationwide Newborn screening program for mucopolysaccharidoses in Taiwan and an update of the “gold standard” criteria required to make a confirmatory diagnosis. Diagnostics (Basel), 11, 1583.

 

  1. Home
  2. SNQ Certified
  3. Certified Services & Products
  4. Hospital
Specialized Medical ServicesNational Biotechnology and Medicine Care Quality Award: 2018 silver

Mucopolysaccharidosis

By using a simple blood smear screening method, potential mucopolysaccharidosis patients can be detected in the neonatal period.
Organization
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
Mucopolysaccharidosis
Mucopolysaccharidosis
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital

Other Certified Items

Identifying High Social Risk Patients
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
>33
10
Integrated Obstetric Care
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
100
1,257
Companion Nurse – LINE Chatbot
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
>94
>98.52
Anticipating Pressure, Empowering Care: Risk Management and Smart Defense Against Pressure Injuries.
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
<0.09
<0.14
Health Promotion & Dementia/Disability Prevention
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
>20,000
4.74
POLE mutation detection in EmCa.
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
100
100
Heart Failure with Preserved Ejection Fraction
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
>95
<0
3D interactive anatomy teaching with AI
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
98
3.3
Alcohol Use Disorder
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
17.6
>74
From MacKay to the Nation: Implementation of Competency- based Pharmacy Education
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
76
114
Identifying High Social Risk Patients
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
>33
10
Integrated Obstetric Care
MacKay Medical Foundation The Presbyterian Church in Taiwan MacKay Memorial Hospital
100
1,257